Valuation: Bioventix PLC

Market Cap 104M 140M 125M 115M 195M 13.29B 199M 1.38B 552M 6.99B 525M 514M 22.05B P/E 2026
11.5x
P/E 2027 * 14x
Enterprise Value 99.6M 133M 119M 110M 186M 12.67B 190M 1.31B 526M 6.66B 501M 490M 21.02B EV / Sales 2026
6.24x
EV / Sales 2027 * 7.71x
Free-Float
92.29%
Yield 2026
9.09%
Yield 2027 * 7.5%
1 day-1.23%
1 month+17.65%
3 months+32.45%
6 months+15.94%
Current year+4.99%
1 week 1,800
Extreme 1800
2,100
1 month 1,600
Extreme 1600
2,100
Current year 1,300
Extreme 1300
2,100
1 year 1,300
Extreme 1300
2,255
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 22/12/2003
Director of Finance/CFO 67 30/06/2020
Director TitleAgeSince
Director/Board Member 67 24/11/2010
Chairman 66 31/10/2004
Director/Board Member 67 30/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
28/04/26 Buy

Chief Financial Officer

66 0.0013%
20/04/26 Free

Chief Executive Officer

9,967 0.1908%
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%-.--%-2.44%-45.58% 140M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.18%+6.79%+42.58%+170.93% 39.45B
Weighted average by Cap. +0.18%+5.44%+47.97%+176.59%

Financials

2026 2027 *
Net sales 12.5M 16.75M 15M 13.8M 23.37M 1.59B 23.8M 165M 66.04M 836M 62.85M 61.51M 2.64B 12.96M 17.36M 15.55M 14.3M 24.23M 1.65B 24.68M 171M 68.47M 867M 65.16M 63.77M 2.73B
Net income 7.1M 9.51M 8.52M 7.84M 13.27M 903M 13.52M 93.44M 37.51M 475M 35.7M 34.94M 1.5B 7.51M 10.06M 9.01M 8.28M 14.03M 955M 14.29M 98.79M 39.66M 502M 37.74M 36.94M 1.58B
Net Debt -4.9M -6.56M -5.88M -5.41M -9.16M -623M -9.33M -64.49M -25.89M -328M -24.64M -24.11M -1.03B -4.62M -6.2M -5.55M -5.1M -8.65M -588M -8.81M -60.87M -24.44M -309M -23.25M -22.76M -976M
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
30/10/26 GBX 2,000.00 -1.23% 17,142
29/10/26 GBX 2,025.00 -1.22% 25,151
28/10/26 GBX 2,050.00 +3.02% 37,222
27/10/26 GBX 1,990.00 +0.76% 21,362
26/10/26 GBX 1,975.00 -1.25% 42,114
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20.00GBP
Average target price
39.00GBP
Spread / Average Target
+95.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock